Suppr超能文献

长期 denosumab 治疗可恢复前臂和肱骨的皮质骨丢失并降低骨折风险:来自 FREEDOM 扩展交叉组的分析。

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.

机构信息

College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Amgen Inc., Thousand Oaks, CA, USA.

出版信息

Osteoporos Int. 2019 Sep;30(9):1855-1864. doi: 10.1007/s00198-019-05020-8. Epub 2019 Jun 14.

Abstract

UNLABELLED

Upper limb fractures (including wrist, forearm, and humerus) represent a significant burden among postmenopausal women with osteoporosis. Up to 7 years of treatment with denosumab resulted in an increase in bone mineral density and decrease in fractures in upper limb sites.

INTRODUCTION

Upper limb (wrist, forearm, and humerus) fractures are a significant burden in osteoporosis, associated with significant morbidity and mortality. Denosumab, a monoclonal antibody against RANK ligand, increases bone mineral density (BMD) and decreases vertebral, nonvertebral, and hip fractures. Here, we evaluated the long-term effect of denosumab treatment on upper limb fracture risk and BMD.

METHODS

In the FREEDOM trial, subjects were randomized 1:1 to receive every-6-month denosumab 60 mg or placebo subcutaneously for 3 years, after which all subjects could receive denosumab for up to 7 years (Extension). Among placebo subjects who completed FREEDOM and enrolled in the Extension, wrist, forearm, humerus, and upper limb fracture rates and rate ratios between different time periods (FREEDOM years 1-3, Extension years 1-3, and Extension years 4-7) were computed. BMD at the ultradistal radius, 1/3 radius, and total radius was analyzed in a subset of subjects in a BMD substudy.

RESULTS

This analysis included 2207 subjects (116 in the BMD substudy). Fracture rates decreased over the 7-year Extension; fracture rate ratios between Extension years 4-7 (denosumab) and FREEDOM years 1-3 (placebo) reduced significantly for the wrist (0.57), forearm (0.57), humerus (0.42), and upper limb (0.52; p < 0.05 for all). Percentage increase in BMD from Extension baseline at the ultradistal radius, 1/3 radius, and total radius was significant by Extension year 7 (p < 0.05 for all).

CONCLUSIONS

Long-term treatment with denosumab decreases upper limb fracture risk and increases forearm BMD, suggesting beneficial effects on both cortical and trabecular bone accruing over time.

摘要

未加标签

绝经后骨质疏松症患者上肢骨折(包括腕部、前臂和肱骨)负担沉重。使用地舒单抗治疗长达 7 年可增加骨密度并减少上肢部位骨折。

引言

上肢(腕部、前臂和肱骨)骨折是骨质疏松症的一个重大负担,与严重的发病率和死亡率相关。地舒单抗是一种针对 RANK 配体的单克隆抗体,可增加骨密度(BMD)并减少椎体、非椎体和髋部骨折。在这里,我们评估了地舒单抗治疗对上肢骨折风险和 BMD 的长期影响。

方法

在 FREEDOM 试验中,受试者按 1:1 随机接受每 6 个月皮下注射地舒单抗 60mg 或安慰剂,持续 3 年,之后所有受试者均可接受地舒单抗治疗长达 7 年(延伸期)。在完成 FREEDOM 并参加延伸期的安慰剂受试者中,计算了腕部、前臂、肱骨和上肢骨折的发生率以及不同时间段(FREEDOM 年 1-3 年、延伸期年 1-3 年和延伸期年 4-7 年)之间的发生率比值。在 BMD 子研究的一部分受试者中分析了桡骨远端、1/3 半径和总半径处的 BMD。

结果

这项分析包括 2207 名受试者(116 名在 BMD 子研究中)。延伸期内骨折发生率下降;延伸期 4-7 年(地舒单抗)与 FREEDOM 年 1-3 年(安慰剂)之间的骨折发生率比值腕部(0.57)、前臂(0.57)、肱骨(0.42)和上肢(0.52)显著降低(所有 p<0.05)。桡骨远端、1/3 半径和总半径处的 BMD 从延伸期基线开始的百分比增加在延伸期 7 年时显著(所有 p<0.05)。

结论

长期使用地舒单抗可降低上肢骨折风险并增加前臂 BMD,表明随着时间的推移对皮质骨和松质骨的累积有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ff/6719332/7637de4dfeb5/198_2019_5020_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验